Moses Goddard
Corporate Officer/Principal at Semma Therapeutics, Inc.
Moses Goddard active positions
| Companies | Position | Start | End |
|---|---|---|---|
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2018-12-17 | - |
| Chief Tech/Sci/R&D Officer | - | 2018-12-17 |
Career history of Moses Goddard
Former positions of Moses Goddard
| Companies | Position | Start | End |
|---|---|---|---|
CytoSolv, Inc.
 CytoSolv, Inc. Pharmaceuticals: OtherHealth Technology CytoSolv, Inc. develops proprietary technology to address wound healing. Its technology involves a mixture of wound-healing factors derived from porcine choroid plexus (CP), a key component of the blood brain barrier, which naturally secretes a variety of proteins into the cerebrospinal fluid responsible for growth, differentiation, nurturing and maintenance of the healing function. The company was founded by Moses Goddard and Christopher D. Thanos in 2009 and is headquartered in Providence, RI. | Director/Board Member | 2008-12-31 | - |
| Founder | 2010-02-09 | - | |
| President | 2010-02-09 | - | |
| Corporate Secretary | 2008-12-31 | - | |
| Treasurer | 2008-12-31 | - |
Statistics
International
| United States | 3 |
Operational
| Director/Board Member | 1 |
| Founder | 1 |
| President | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
CytoSolv, Inc.
CytoSolv, Inc. Pharmaceuticals: OtherHealth Technology CytoSolv, Inc. develops proprietary technology to address wound healing. Its technology involves a mixture of wound-healing factors derived from porcine choroid plexus (CP), a key component of the blood brain barrier, which naturally secretes a variety of proteins into the cerebrospinal fluid responsible for growth, differentiation, nurturing and maintenance of the healing function. The company was founded by Moses Goddard and Christopher D. Thanos in 2009 and is headquartered in Providence, RI. | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Moses Goddard
- Experience
